Bila Xitan Jiaonang (吡拉西坦胶囊)吡拉西坦胶囊
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 北京曙光药业有限责任公司Chinese legal name: 北京曙光药业有限责任公司
主要成分Active Ingredients
- 吡拉西坦Bila Xitan
药物知识说明
吡拉西坦是一种在国家药监局注册认定的药品。该药品含有吡拉西坦-e6b3f02b等成分。
该药品关联的活性成分包括：吡拉西坦Bila Xitan。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：北京曙光药业有限责任公司Chinese legal name: 北京曙光药业有限责任公司。
您可以探索含有相同成分的其他药品：吡拉西坦-e6b3f02b成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 吡拉西坦胶囊) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 吡拉西坦Bila Xitan.
Manufacturers recorded for this product: 北京曙光药业有限责任公司Chinese legal name: 北京曙光药业有限责任公司.
Explore other medicines containing the same ingredient: 吡拉西坦 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 吡拉西坦胶囊Recorded Chinese name: 吡拉西坦胶囊
- 剂型Dosage form: 胶囊剂Capsules
- 规格Specification: 0.4g0.4 g
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 北京曙光药业有限责任公司Chinese legal name: 北京曙光药业有限责任公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H11022585
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H11022585
Manufacturer
Chinese legal name: 北京曙光药业有限责任公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Protect from light and keep tightly closed.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H11022585
生产企业
北京曙光药业有限责任公司(国产)
适应症
适用于急、慢性脑血管疾病、脑外伤、各种中毒性脑疾病等多种原因所致的记忆减退及轻、中度脑功能障碍。也用于儿童智能发育迟缓。
用法用量
口服。成人，每次0.8-1.2g（2-3粒）每日2-3次，4-8周为一疗程。老年人、儿童酌减。
不良反应
1．消化道不良反应常见有恶心、腹部不适、纳差、腹胀、腹痛等，症状的轻重与用药剂量直接相关。
禁忌
1．锥体外系疾病、Huntington等舞蹈症者禁用。 2．对本品过敏者禁用。
注意事项
肝、肾功能障碍者慎用并应适当减少剂量。与华法林合用时，应当减少剂量，防止出血并发症的发生。
贮藏
遮光，密封保存。
规格
0.4g
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.